Autolus Therapeutics PLC(AUTL),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

AUTL Autolus Therapeutics PLC

Closed Good Friday 04-17 16:00:00 EDT

1.43

+0.08

+5.93%

盘后1.49

+0.06+4.20%

18:20 EDT

High1.49	Low1.33	Vol1.17M
Open1.34	D1 Closing1.35	Amplitude11.48%
Mkt Cap380.56M	Tradable Cap197.47M	Total Shares266.13M
T/O1.67M	T/O Rate0.84%	Tradable Shares138.09M
P/B0.89	ROE-81.91%	EPS-0.86
52wk High5.25	52wk Low1.11	P/E-1.65
Dividend0.00	Div.Yield0.00	ROA-25.99%

Invest in Global Markets with Tiger Brokers!

Open App

{"stockData":{"symbol":"AUTL","market":"US","secType":"STK","nameCN":"Autolus Therapeutics PLC","latestPrice":1.43,"timestamp":1744920000000,"preClose":1.35,"halted":0,"volume":1166580,"hourTrading":{"tag":"盘后","latestPrice":1.49,"preClose":1.43,"latestTime":"18:20 EDT","volume":12612,"amount":18068.456,"timestamp":1744928451335},"delay":0,"floatShares":138093434,"shares":266128900,"eps":-0.864795,"marketStatus":"Closed Good Friday","change":0.08,"latestTime":"04-17 16:00:00 EDT","open":1.34,"high":1.485,"low":1.33,"amount":1665677.104794,"amplitude":0.114815,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.864795,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1745222400000},"marketStatusCode":7,"adr":1,"adrRate":1,"listingDate":1529640000000,"exchange":"NASDAQ","adjPreClose":1.35,"postHourTrading":{"tag":"盘后","latestPrice":1.49,"preClose":1.43,"latestTime":"18:20 EDT","volume":12612,"amount":18068.456,"timestamp":1744928451335},"volumeRatio":0.5784116185764406,"impliedVol":0.7376,"impliedVolPercentile":0.255},"requestUrl":"/m/hq/s/AUTL","defaultTab":"news","newsList":[{"id":"2528364742","title":"European Equities Traded in the US as American Depositary Receipts Modestly Higher in Thursday Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2528364742","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528364742?lang=en_us&edition=full_marsco","pubTime":"2025-04-17 23:05","pubTimestamp":1744902319,"startTime":"0","endTime":"0","summary":"European equities traded in the US as American depositary receipts were modestly higher late Thursday morning, rising 0.31% to 1,331.70 on the S&P Europe Select ADR Index.From continental Europe, the gainers were led by medical device maker EDAP TMS  and telecommunications company Ericsson , which rose 2.7% and 2.3% respectively. They were followed by biopharmaceutical company Cellectis  and telecommunications operator Telefonica , which were up 2.1% and 2% respectively.The decliners from continental Europe were led by pharmaceutical company Novo Nordisk  and furniture maker Natuzzi , which lost 8.3% and 3.2% respectively. They were followed by 3D printer company Materialise  and biopharmaceutical company Genfit , which dropped 2.4% and 1.8% respectively.From the UK and Ireland, the gainers were led by insurance company Prudential  and biotech firm Autolus Therapeutics , which increased 3.7% and 3.3% respectively. They were followed by biopharmaceutical company Mereo BioPharma Group  a","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4023","LU1093756168.USD","LU1829250122.USD","MTLS","IE00BKVL7J92.USD","NVO.AU","NVO","BK4020","EDAP","BK4588","BK4554","GNFT","BK4007","BK4139","BK4082","TEF","LU1162221912.USD","CLLS","ERIC","BK4505","LU0320765646.SGD","BK4115","MREO","LU0072461881.USD","BK7104","AFG","BK4515","NCNA","BP","BK4201","LU1093756325.SGD","BK4107","BK4599","BK4117","BK4162","BK4546","PUK","LU0162691827.USD","BK4532","AUTL","AKTX","BDRX","AMRN","NTZ","BK4585","LU0154236417.USD","BK4095","BK4591","IE00BZ1G4Q59.USD"],"gpt_icon":1},{"id":"2527221147","title":"April 2025's Top Penny Stocks To Watch","url":"https://stock-news.laohu8.com/highlight/detail?id=2527221147","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527221147?lang=en_us&edition=full_marsco","pubTime":"2025-04-16 20:04","pubTimestamp":1744805095,"startTime":"0","endTime":"0","summary":"The market is up 8.4% in the last 7 days, with all sectors gaining ground, and over the past 12 months, it has risen by 5.9%, with earnings forecasted to grow by 13% annually. Penny stocks may be a throwback term, but the opportunities they represent are far from old news; these typically smaller or newer companies present an underappreciated chance for growth at lower price points. When combined with strong balance sheets and solid fundamentals, penny stocks can offer upside without many of the risks often associated with this corner of the market.Overview: Ardelyx, Inc. is a biopharmaceutical company that discovers, develops, and commercializes medicines for unmet medical needs in the United States and internationally, with a market cap of approximately $1.09 billion.Evaluate Ardelyx's prospects by accessing our earnings growth report.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/april-2025s-top-penny-stocks-120455716.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SB","BABB","BK4123","BK4023","BK4209","ARDX","BK4509","BK4139","TUYA","BK4021","BK4563","BK4505","AUTL","PL","BK4526"],"gpt_icon":1},{"id":"2524014307","title":"European Equities Traded in the US as American Depositary Receipts Tread Water in Tuesday Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2524014307","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524014307?lang=en_us&edition=full_marsco","pubTime":"2025-04-01 23:11","pubTimestamp":1743520287,"startTime":"0","endTime":"0","summary":"European equities traded in the US as American depositary receipts were treading water late Tuesday morning, edging 0.02% higher to 1,397.86 on the S&P Europe Select ADR Index.From continental Europe,","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IE00BMPRXN33.USD","NOK","BK4117","DBVT","TRIB","NCNA","BK4547","BK4082","ADAP","BK4139","SLN","BK4207","BK4020","BK4585","LU0320765992.SGD","AUTL","GNFT","EQNR","LU0109394709.USD","BK4521","WPP.AU","SAN.AU","EDAP","AKTX","IE00BMPRXR70.SGD","BK4588","BK4009","WPP","BK4007","EVAX","BCYC","BK7142","SAN","LU0889565916.HKD","BK4201","BK4107","AFG","ASND"],"gpt_icon":0},{"id":"2524411194","title":"Autolus Therapeutics Plc : Truist Securities Cuts Target Price to $10 From $11","url":"https://stock-news.laohu8.com/highlight/detail?id=2524411194","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524411194?lang=en_us&edition=full_marsco","pubTime":"2025-04-01 19:09","pubTimestamp":1743505744,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250401:nFWN3QF0IF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","AUTL"],"gpt_icon":0},{"id":"2523928069","title":"Truist Adjusts Price Target on Autolus Therapeutics to $10 From $11, Maintains Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2523928069","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523928069?lang=en_us&edition=full_marsco","pubTime":"2025-03-31 22:27","pubTimestamp":1743431265,"startTime":"0","endTime":"0","summary":"Autolus Therapeutics (AUTL) has an average rating of buy and mean price target of $9.99, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LENZ","AUTL"],"gpt_icon":0},{"id":"2521960472","title":"Wells Fargo Keeps Their Buy Rating on Autolus Therapeutics (AUTL)","url":"https://stock-news.laohu8.com/highlight/detail?id=2521960472","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521960472?lang=en_us&edition=full_marsco","pubTime":"2025-03-21 17:16","pubTimestamp":1742548587,"startTime":"0","endTime":"0","summary":"Wells Fargo analyst Yanan Zhu maintained a Buy rating on Autolus Therapeutics (AUTL – Research Report) yesterday and set a price target of $6.00. T...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/wells-fargo-keeps-their-buy-rating-on-autolus-therapeutics-autl?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/wells-fargo-keeps-their-buy-rating-on-autolus-therapeutics-autl?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AUTL"],"gpt_icon":0},{"id":"2521424186","title":"Autolus Therapeutics PLC (AUTL) Q4 2024 Earnings Call Highlights: Financial Growth Amid Rising Costs","url":"https://stock-news.laohu8.com/highlight/detail?id=2521424186","media":"GuruFocus.com","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521424186?lang=en_us&edition=full_marsco","pubTime":"2025-03-21 15:03","pubTimestamp":1742540590,"startTime":"0","endTime":"0","summary":"Cash Equivalents and Marketable Securities: $588 million at year-end 2024, up from $239 million at December 31, 2023.Loss from Operations: $241.4 million for the year ending December 31, 2024, compared to $179.7 million in 2023.Cost of Sales: $11.4 million following BLA approval for obe-cel.Research and Development Expenses: $138.4 million for the year ending December 31, 2024, up from $130.5 million in 2023.Selling, General and Administrative Expenses: $101.1 million for the year, up from $46.7 million in 2023.Milestone Payments: $30 million received from Blackstone; GBP10 million regulatory milestone payment made under UCLB license agreement.GuruFocus has detected 1 Warning Sign with AUTL.Autolus Therapeutics PLC  successfully launched AUCATZYL in the US, achieving FDA approval ahead of schedule without requiring a REMS program.Autolus Therapeutics PLC  has authorized 33 centers to deliver AUCATZYL, covering approximately 60% of the target patient population in the US.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/autolus-therapeutics-plc-autl-q4-070310251.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BNTX","AUTL"],"gpt_icon":0},{"id":"2521423723","title":"Q4 2024 Autolus Therapeutics PLC Earnings Call","url":"https://stock-news.laohu8.com/highlight/detail?id=2521423723","media":"Thomson Reuters StreetEvents","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521423723?lang=en_us&edition=full_marsco","pubTime":"2025-03-21 13:44","pubTimestamp":1742535882,"startTime":"0","endTime":"0","summary":"Christian Itin; Chief Executive Officer, Executive Director; Autolus Therapeutics PLC. Rob Dolski; Chief Financial Officer; Autolus Therapeutics PLC. Hello ladies and gentlemen and welcome to the Autolus Therapeutics call to discuss its full year 2024 financial results and business updates. As a reminder, this conference call is being recorded.I would now like to turn the conference over to your host, Amanda Cray. Please go ahead.Thank you very much, Amanda, and welcome everybody to our fourth quarter 2024 financial results update. So first off, obviously, we had a very successful 2024 which sets us up well for the 2025 that we're already in, a few months now. First of all, I'd like to just highlight kind of the key objectives that we have for the year.So the primary objective clearly is to execute a successful commercial launch for AUCATZYL, and we're doing really well and advancing well on that. We'll provide a bit of an update as we go","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/q4-2024-autolus-therapeutics-plc-054442135.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["AUTL"],"gpt_icon":0},{"id":"1107587882","title":"Stock Track | Autolus Therapeutics Surges 5.07% After-Hours on Strong 2024 Results and AUCATZYL Launch Success","url":"https://stock-news.laohu8.com/highlight/detail?id=1107587882","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1107587882?lang=en_us&edition=full_marsco","pubTime":"2025-03-21 06:08","pubTimestamp":1742508506,"startTime":"0","endTime":"0","summary":"Autolus Therapeutics PLC  saw its stock price soar 5.07% in after-hours trading on Thursday, following the release of its fourth quarter and full-year 2024 financial results and business updates. The company reported significant progress in its commercial launch and pipeline development, boosting investor confidence.The positive financial results, successful AUCATZYL launch, and promising outlook for Autolus Therapeutics have clearly resonated with investors, driving the significant after-hours ","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["AUTL"],"gpt_icon":0},{"id":"1190418824","title":"Stock Track | Autolus Therapeutics Plummets 5.15% on Wider Q4 Loss and Increased Annual Expenses","url":"https://stock-news.laohu8.com/highlight/detail?id=1190418824","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1190418824?lang=en_us&edition=full_marsco","pubTime":"2025-03-20 23:30","pubTimestamp":1742484651,"startTime":"0","endTime":"0","summary":"Shares of Autolus Therapeutics PLC  plummeted 5.15% in pre-market trading on Thursday following the release of its fourth quarter and full-year 2024 financial results, which fell short of analyst expectations.The biopharmaceutical company, which recently launched its FDA-approved CAR-T therapy AUCATZYL, reported a wider-than-expected loss for the fourth quarter. Autolus posted a GAAP earnings per share  loss of $0.86, significantly missing analysts' estimates of a $0.20 loss. This represents a c","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["AUTL"],"gpt_icon":0},{"id":"1183047214","title":"Stock Track | Autolus Therapeutics Plummets 5.15% as Q4 Losses Widen, Missing Estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=1183047214","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1183047214?lang=en_us&edition=full_marsco","pubTime":"2025-03-20 23:30","pubTimestamp":1742484628,"startTime":"0","endTime":"0","summary":"Shares of Autolus Therapeutics PLC  plunged 5.15% in Thursday's pre-market trading session following the release of its fourth quarter and full-year 2024 financial results, which fell short of analyst expectations. The biopharmaceutical company, which recently launched its FDA-approved CAR-T therapy AUCATZYL, reported a wider-than-anticipated loss for the quarter ended December 31, 2024.Despite the disappointing financial results, Autolus highlighted several positive developments in its business","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["AUTL"],"gpt_icon":0},{"id":"2520454260","title":"Autolus Therapeutics PLC reports results for the quarter ended December 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2520454260","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520454260?lang=en_us&edition=full_marsco","pubTime":"2025-03-20 21:31","pubTimestamp":1742477518,"startTime":"0","endTime":"0","summary":"Autolus Therapeutics PLC reports results for the quarter ended December 31 - Earnings SummaryAutolus Therapeutics PLC AUTL.OQ reported a quarterly adjusted loss of 10 cents per share for the quarter e","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250320:nL8N3Q31DY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AUTL"],"gpt_icon":0},{"id":"1106157463","title":"Stock Track | Autolus Therapeutics Plunges 5.12% Pre-market Following Q4 Earnings Miss and Wider Annual Losses","url":"https://stock-news.laohu8.com/highlight/detail?id=1106157463","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1106157463?lang=en_us&edition=full_marsco","pubTime":"2025-03-20 20:02","pubTimestamp":1742472165,"startTime":"0","endTime":"0","summary":"Shares of Autolus Therapeutics PLC  tumbled 5.12% in pre-market trading on Thursday after the company reported its fourth quarter and full-year 2024 financial results, which fell short of analyst expectations.The biopharmaceutical company, which recently launched its FDA-approved CAR-T therapy AUCATZYL, posted a wider net loss for the year ended December 31, 2024. The company reported a net loss of $220.7 million, or $0.86 per share, compared to a net loss of $208.4 million, or $1.20 per share, ","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["AUTL"],"gpt_icon":0},{"id":"1170360116","title":"Stock Track | Autolus Therapeutics Plunges 5.12% Pre-Market on Wider-Than-Expected Q4 Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=1170360116","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1170360116?lang=en_us&edition=full_marsco","pubTime":"2025-03-20 20:02","pubTimestamp":1742472165,"startTime":"0","endTime":"0","summary":"Autolus Therapeutics PLC  saw its shares plummet 5.12% in pre-market trading on Thursday following the release of its fourth quarter and full year 2024 financial results. The biopharmaceutical company, focused on developing next-generation programmed T cell therapies, reported a wider-than-expected loss for the quarter.According to the company's earnings report, Autolus posted a GAAP earnings per share  loss of $0.86 for Q4 2024, significantly missing analysts' estimates of a $0.20 loss. This re","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["AUTL"],"gpt_icon":0},{"id":"1105330365","title":"Stock Track | Autolus Therapeutics Soars 7.22% Pre-Market on Strong 2024 Results and Positive Outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=1105330365","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1105330365?lang=en_us&edition=full_marsco","pubTime":"2025-03-20 19:36","pubTimestamp":1742470595,"startTime":"0","endTime":"0","summary":"Autolus Therapeutics PLC  saw its stock surge 7.22% in pre-market trading on Thursday following the release of its fourth quarter and full-year 2024 financial results and business updates. The company reported significant progress in its commercial launch and pipeline development, boosting investor confidence.The positive financial results and promising outlook for Autolus Therapeutics have clearly resonated with investors, driving the significant pre-market stock price increase. As the company ","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Stock Track | Autolus Therapeutics Soars 7.22% Pre-Market on Strong 2024 Results and Positive Outlook","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["AUTL"],"gpt_icon":0},{"id":"2520458927","title":"Autolus Therapeutics Launches AUCATZYL® in U.S. Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2520458927","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520458927?lang=en_us&edition=full_marsco","pubTime":"2025-03-20 19:35","pubTimestamp":1742470509,"startTime":"0","endTime":"0","summary":"Autolus Therapeutics ( ($AUTL) ) has issued an announcement. Autolus Therapeutics reported its financial results for the year ended December 31, 20...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/autolus-therapeutics-launches-aucatzyl-in-u-s-market?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/autolus-therapeutics-launches-aucatzyl-in-u-s-market?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","AUTL","LENZ"],"gpt_icon":0},{"id":"2520305294","title":"Autolus Therapeutics Q4 2024 GAAP EPS $(0.86) Misses $(0.20) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2520305294","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520305294?lang=en_us&edition=full_marsco","pubTime":"2025-03-20 19:15","pubTimestamp":1742469316,"startTime":"0","endTime":"0","summary":"Autolus Therapeutics Q4 2024 GAAP EPS $(0.86) Misses $(0.20) Estimate","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/03/44413413/autolus-therapeutics-q4-2024-gaap-eps-0-86-misses-0-20-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AUTL","LENZ"],"gpt_icon":0},{"id":"2520437679","title":"Press Release: Autolus Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2520437679","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520437679?lang=en_us&edition=full_marsco","pubTime":"2025-03-20 19:00","pubTimestamp":1742468400,"startTime":"0","endTime":"0","summary":"on track with 33 authorized treatment centers as of March 19, 2025,-- Obe-cel MHRA and EMA marketing authorizations expected in H2 2025. -- Initial six patients dosed in Phase 1 dose confirmation trial in Systemic. -- Company to provide clinical development program updates, including plans. for expansion in autoimmune diseases, at R&D investor event to be held on. call participants should pre-register using the link at the bottom of. \"As we begin 2025, we have two key objectives: execute on the commercial launch of AUCATZYL in adult ALL both in the U.S. and entering new markets; and establish the next wave of investments to expand the obe-cel opportunity, advance our clinical pipeline and drive future growth. We look forward to discussing our plans to continue to expand our clinical pipeline and strategy at our R&D event in April.\".  for the treatment of adult patients with relapsed or","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4107","R","BK4543","BK4139","AUTL","BK4181","BK4218","NICE","IE00BFMHRM44.USD","EBMT","BK4023","SOHO","BK4232","BK4533","BK4077","LU1571399168.USD","BK4585","LU1699723380.USD","SLE","ASH","LU2355687059.USD","BK4211","BK4109","LU0985320562.USD","BK4588","BK4566","LU2463526074.USD","BK4022","ALL","LENZ"],"gpt_icon":0},{"id":"2520675437","title":"Autolus Therapeutics PLC  expected to post a loss of 21 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2520675437","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520675437?lang=en_us&edition=full_marsco","pubTime":"2025-03-18 20:40","pubTimestamp":1742301606,"startTime":"0","endTime":"0","summary":"Autolus Therapeutics PLC  expected to post a loss of21cents a share - Earnings Preview Autolus Therapeutics PLC AUTL.OQ, AUTL.O is expected to show a rise in quarterly revenue when it reports  results","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250318:nL8N3Q113D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AUTL"],"gpt_icon":0},{"id":"2520889517","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2520889517","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520889517?lang=en_us&edition=full_marsco","pubTime":"2025-03-17 18:00","pubTimestamp":1742205600,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.·Bitcoin Depot Inc.                               4Q       .02   8:05 AM. ·IHS Hldg Ltd.                                    4Q       .01   6:00 AM","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AEVA","HYPR","OPTN","LPRO","CAL","FIVE","LQDA","ASO","LEN.B","BLTE","GLUE","LAR","SIG","DRI","KLC","OSS","CMC","MSIF","CELC","STTK","DERM","NOA","RWAY","SGMO","INO","ABSI","KOPN","LXEO","RANI","RBOT","SAIC","IMTX","NRXP","BCAB","AUTL","OABI","CBUS","DMAC","STNE","PL","SCPH","ANRO","CNTX","FLUX","PHUN","SPRY","BTM","LVTX"],"gpt_icon":1}],"profile":{"websiteUrl":"http://www.autolus.com","stockEarnings":[{"period":"1week","weight":0.2544},{"period":"1month","weight":-0.2011},{"period":"3month","weight":-0.3559},{"period":"6month","weight":-0.7021},{"period":"1year","weight":-0.7045},{"period":"ytd","weight":-0.3915}],"compareEarnings":[{"period":"1week","weight":0.0035},{"period":"1month","weight":-0.0617},{"period":"3month","weight":-0.1191},{"period":"6month","weight":-0.0995},{"period":"1year","weight":0.0517},{"period":"ytd","weight":-0.1018}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. Autolus Therapeutics plc was incorporated in 2014 and is headquartered in London, the United Kingdom.","yearOnYearQuotes":[{"month":1,"riseRate":0.142857,"avgChangeRate":-0.12202},{"month":2,"riseRate":0.142857,"avgChangeRate":-0.090867},{"month":3,"riseRate":0.428571,"avgChangeRate":-0.029231},{"month":4,"riseRate":0.285714,"avgChangeRate":-0.049784},{"month":5,"riseRate":0.666667,"avgChangeRate":0.165215},{"month":6,"riseRate":0.5,"avgChangeRate":-0.051509},{"month":7,"riseRate":0.285714,"avgChangeRate":0.021369},{"month":8,"riseRate":0.571429,"avgChangeRate":0.050484},{"month":9,"riseRate":0.285714,"avgChangeRate":-0.103208},{"month":10,"riseRate":0.285714,"avgChangeRate":0.020581},{"month":11,"riseRate":0.571429,"avgChangeRate":0.167742},{"month":12,"riseRate":0.142857,"avgChangeRate":-0.098112}],"exchange":"NASDAQ","name":"Autolus Therapeutics PLC","nameEN":"Autolus Therapeutics PLC"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.33.2","shortVersion":"4.33.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Autolus Therapeutics PLC(AUTL),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Autolus Therapeutics PLC(AUTL) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Autolus Therapeutics PLC,AUTL,Autolus Therapeutics PLC股票,Autolus Therapeutics PLC股票老虎,Autolus Therapeutics PLC股票老虎国际,Autolus Therapeutics PLC行情,Autolus Therapeutics PLC股票行情,Autolus Therapeutics PLC股价,Autolus Therapeutics PLC股市,Autolus Therapeutics PLC股票价格,Autolus Therapeutics PLC股票交易,Autolus Therapeutics PLC股票购买,Autolus Therapeutics PLC股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Autolus Therapeutics PLC(AUTL),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Autolus Therapeutics PLC(AUTL) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction